Coverage of "Outlook Therapeutics" on Cryptosearcher: the stories and the context behind them.
Outlook Therapeutics shares surged after the FDA cleared Lytenava for treating wet AMD, the first approved bevacizumab eye treatment in the U.S. The stock jumped nearly 9% pre-market.
July 27, 2026
